Pipeline
AZ01 is a long acting form of interferon β, the current gold standard therapy for multiple sclerosis patients. Construction with ALLOZYNE’s, E. coli based, CAESAR platform allows for customization of the position, size and architecture of the conjugated polyethylene glycol (PEG) moiety, resulting in an improved half-life compared to commercially available interferon β molecules. This will result in a less frequent dosing regimen for patients, fewer side effects and likely improvement in patient compliance.
AZ17 is a bispecific antibody expressed in E. coli, which simultaneously inhibits two cytokines involved in the TH17 pathway through a novel mechanism of action. The site specific linkage of AZ17’s two binding domains is a product of ALLOZYNE’s proprietary CAESAR biociphering platform. Potential therapeutic use of AZ17 is for chronic inflammatory conditions, such as Crohn’s disease, and the compound is currently being validated in a variety of animal models.
AZ21 is a long acting form of FGF21 which is currently being developed in both the CAESAR (E. coli) and VIGENÈRE (mammalian) platforms. AZ21 can overcome the need for multiple and frequent administration by its conjugation to a known and validated chemical moiety, polyethylene glycol (PEG), proven to elicit extended elimination half-life and reduced clearance.
FGF21, a member of the fibroblast growth factor (FGF) family of proteins, stimulates glucose uptake in adipocytes and has a potential therapeutic application in Type II Diabetes. Animal studies have shown that treatment with FGF21 lowers plasma glucose and increases insulin sensitivity but the beneficial effects require repeat or prolonged exposure and are not observed after a single administration.
FGF21, a member of the fibroblast growth factor (FGF) family of proteins, stimulates glucose uptake in adipocytes and has a potential therapeutic application in Type II Diabetes. Animal studies have shown that treatment with FGF21 lowers plasma glucose and increases insulin sensitivity but the beneficial effects require repeat or prolonged exposure and are not observed after a single administration.
